Supernus Pharmaceuticals to Engage in Investor Conferences
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), a biopharmaceutical company renowned for its commitment to treating diseases related to the central nervous system (CNS), is excited to announce its participation in a pair of significant investor conferences in the upcoming weeks. Jack Khattar, the President and CEO of the company, will take the stage to share insights into the company's ongoing developments and future plans.
Engagement at Barclays Global Healthcare Conference
One of the primary events on the agenda is the Barclays Global Healthcare Conference. This engaging event is scheduled for forthcoming weeks.
Details of the Barclays Conference
During this conference, Mr. Khattar will participate in a fireside chat, which is set to occur at 12:30 p.m. ET.
Location Information
This notable conference will take place at the Loews Miami Beach Hotel. This venue is an ideal location for networking and discussing pivotal issues in the healthcare sector.
Participation in Jefferies Biotech on the Beach Summit
Following the Barclays event, Supernus Pharmaceuticals will also be present at the Jefferies Biotech on the Beach Summit. This summit is known for attracting leading experts and investors in the biotech field.
Details of the Jefferies Summit
Mr. Khattar will present on Wednesday at this influential gathering, emphasizing the company's trajectory in CNS therapies.
Venue for the Summit
The Ritz-Carlton South Beach is the chosen venue for the Jefferies summit, known for its esteemed atmosphere and vibrant setting.
Investor Meeting Arrangements
Investors interested in arranging discussions with the management team during these conferences are encouraged to reach out to the conference coordinators directly. This is an excellent opportunity to gain in-depth insights into the company's direction.
Supernus Pharmaceuticals: Company Overview
Supernus Pharmaceuticals is at the forefront of developing innovative medical therapies aimed at treating CNS disorders. The company's portfolio includes an array of products already approved for conditions such as ADHD and epilepsy, alongside ongoing development efforts for new treatments aimed at depression and complex neurological disorders.
Diverse Product Portfolio
With a focus on conditions like dyskinesia, migraines, and chronic sialorrhea, Supernus is actively expanding its therapeutic offerings. The commitment to improving the lives of patients is central to the company's mission.
Continuing Commitment to Innovation
The ongoing quest for new CNS therapies reflects the company's dedication to innovation and excellence within this vital area of healthcare. Supernus Pharmaceuticals remains dedicated to furthering its research initiatives to bring new hope to patients.
Frequently Asked Questions
What is Supernus Pharmaceuticals known for?
Supernus Pharmaceuticals is focused on developing and commercializing treatments for central nervous system diseases.
When will Supernus participate in the investor conferences?
Supernus will participate in the Barclays Global Healthcare Conference and the Jefferies Biotech on the Beach Summit.
Who is the main speaker at the conferences?
Jack Khattar, the President and CEO, will be representing Supernus at both conferences.
What types of conditions does Supernus treat?
The company offers treatments for ADHD, epilepsy, dyskinesia, and other CNS disorders.
How can investors arrange a meeting with Supernus management?
Investors can contact the respective conference coordinators to set up meetings.
